Clinical trials
Cytomegalovirus clinical trials
Below are recruiting cytomegalovirus clinical trials, each written for real people, not researchers. We’re tracking 58 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06812598Recruiting
Extended letermovir to prevent CMV after stem cell transplant
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
Suzhou, JiangsuAges 18 years+ - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT07014319RecruitingPhase 2
Maribavir for CMV in lymphoma patients on bispecific antibodies
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
SeoulAges 19 years+ - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT07679412Recruiting
CMV Retinitis Trial: Your Own Cells vs. Resistant Virus
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
SeoulAges 19 years+ - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT07009548Enrolling by invitationPhase 4
CytoGam for CMV in solid organ transplant recipients
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Pittsburgh, PennsylvaniaAges 18–75 - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years
Hear when a new Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cytomegalovirus?
- Yes. Clin2 currently lists 58 recruiting cytomegalovirus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cytomegalovirus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cytomegalovirus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.